Search

Displaying results 8851 - 8860 of 10000 in total
  1. Drug

    AEG35156

    go.drugbank.com/drugs/DB06184
    Investigational

    AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. … This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis.

  2. Drug

    Imgatuzumab

    go.drugbank.com/drugs/DB14884
    Investigational

    Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

  3. Drug

    Hopantenic acid

    go.drugbank.com/drugs/DB14044
    Experimental

    Hopantenic acid has a unique spectrum of pharmacological effects (nootropic, anticonvulsant, mild activating) in the absence of addiction, hyperstimulation or withdrawal syndrome. [A33115]

    Synonyms: D-Homopantothenic acid, N-pantoyl-GABA
  4. Drug

    Elsubrutinib

    go.drugbank.com/drugs/DB18850
    Investigational

    Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants … With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State).

  5. Drug

    Denenicokin

    go.drugbank.com/drugs/DB12908
    Investigational

    Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).

  6. Drug

    Indatuximab ravtansine

    go.drugbank.com/drugs/DB16195
    Investigational

    Indatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).

  7. Drug

    SB-269970

    go.drugbank.com/drugs/DB13988
    Experimental

    In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817] … SB-269970 is an experimental drug developed by GlaxoSmithKline.

  8. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  9. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    μ (mu) - and δ (delta) -opioid receptors. … Clinical studies demonstrates effectiveness of vitex agnus-castus fruit extract in the management of premenstrual stress syndrome (PMS) and cyclical breast pain (mastalgia).

  10. Drug

    Linopristin

    go.drugbank.com/drugs/DB19296
    Experimental

    Linopristin is an antibiotic of the streptogramin B class. It is one part of the combination product NXL 103, along with [Virginiamycin M1]. … The combination product was under investigation in clinical trials NCT00653172 and NCT00949130 for treatment of various bacterial infections.